Sleep Disorders Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Sleep Disorders Treatment Market Trends and Insights

Rising Global Burden of Insomnia & Sleep Apnea Driven by Ageing, Obesity and Mental-Health Stressors

An estimated 30 million to 90 million Americans live with OSA, yet only 6 million have been formally diagnosed, illustrating a deep pool of untreated need that sustains the sleep disorder treatment market. The obesity epidemic intensifies OSA incidence, and December 2024 FDA clearance of tirzepatide created the first pharmacologic pathway for obese OSA patients, linking metabolic control to respiratory improvement^{[1]U.S. Food and Drug Administration, “Zepbound (tirzepatide) Approved for Obstructive Sleep Apnea,” fda.gov}. Pandemic-era anxiety and depression elevated chronic insomnia across every major region, with DORAs showing 87.5% response rates in psychiatric populations and reinforcing clinician confidence in newer mechanisms. ResMed now monitors 28 million cloud-connected devices and captures 20 billion nights of sleep data that feed proprietary AI engines, scaling personalised therapy adjustments in real time. Among older adults, preference is shifting to non-invasive, digitally delivered programs such as SleepioRx—cleared by FDA in August 2024—which reduce pill burden while maintaining durable efficacy.

Enhanced Screening and Public-Awareness Programs Accelerating Diagnosis Rates

System-wide screening protocols are raising detection in primary care and consumer settings. Samsung’s collaboration with Stanford Medicine embeds algorithmic sleep-apnea screening in smartphones, signalling a move from laboratory polysomnography to home-based triage. In February 2024 the FDA cleared EnsoData’s pulse-oximetry AI platform, enabling lower-cost identification of OSA risk in resource-limited environments. Japan’s first insomnia drug approval in a decade—QUVIVIQ in September 2024—followed national media campaigns that highlighted untreated sleep disorders affecting 20% of adults and spurred physician education. Start-ups such as Sleep Cycle launched clinical studies in June 2025 to validate smartphone-based apnea screening, potentially reaching rural communities lacking specialty clinics. FDA clearance of ResMed’s NightOwl home test adds medical-grade support to direct-to-consumer pathways, shortening time-to-therapy and expanding the sleep disorder treatment market.

Launch of Novel Pharmacological Classes Expanding Therapeutic Options

DORAs represent the most consequential advance in sleep pharmacotherapy since benzodiazepines. Daridorexant, lemborexant and suvorexant consistently demonstrate fewer complex sleep behaviours and less next-day impairment than Z-drugs, as shown in FDA Adverse Event Reporting System analyses. China’s May 2025 approval of DAYVIGO (lemborexant) opens an addressable base of 172.5 million adult insomnia patients, illustrating the scale of opportunity when safety concerns are mitigated. Next-generation agonists are moving swiftly: Takeda’s oveporexton produced significant Phase 2b gains in narcolepsy type 1, while Alkermes’ alixorexton targets idiopathic hypersomnia in Phase II/III trials^{[2]Takeda Pharmaceutical Company, “Oveporexton Phase 2b Data Published,” takeda.com}. The pipeline further includes seltorexant, an orexin-2 antagonist positioned for major depressive disorder with co-morbid insomnia, blurring traditional indication boundaries and enlarging the sleep disorder treatment market footprint. High compliance rates—87% in long-term cohorts—underscore the clinical goodwill earned by these agents, driving formulary inclusion and insurer acceptance.

Continuous Innovation in Device-Based and Digital Therapeutics Improving Outcomes & Adherence

Device developers are redefining adherence, historically the Achilles heel of CPAP therapy. In February 2024 the FDA cleared Neurovalens’ Modius Sleep, a head-worn neuromodulator that influences circadian centres without pharmaceuticals and delivers measurable gains in sleep efficiency within six weeks. Researchers at University of Cincinnati introduced VortexPAP, which stabilises airway pressure without a tight facial interface, promising relief for users who abandon conventional masks. Digital therapeutics command growing mindshare: SleepioRx’s cognitive-behavioural algorithm achieves healthy-sleep benchmarks in 76% of users, validating non-drug pathways that reduce adverse-event liabilities. Implantables are broadening choices for CPAP-intolerant cohorts, with Nyxoah’s Genio tongue stimulator gaining its first UK use case in December 2024 and leveraging Bluetooth control for patient-tailored therapy. Real-time data streaming from ResMed’s AirSense line reached 87% compliance when automated coaching was layered onto nightly data dashboards, showcasing how AI can convert raw signals into behaviour change that sustains the sleep disorder treatment market.

Safety Concerns and Dependency Risks Associated with Long-Term Hypnotic Pharmacotherapy

Regulators are tightening oversight of traditional hypnotics, curbing label expansions and encouraging safer alternatives. In March 2024 the FDA issued a complete-response letter to Vanda’s HETLIOZ jet-lag supplement, signalling unwillingness to tolerate vague benefit-risk profiles in sleep medicine^{[3]Federal Register, “Complete Response Letter for HETLIOZ,” federalregister.gov}. Benzodiazepines and Z-drugs continue showing higher incidences of complex behaviours such as sleep-driving, prompting guideline revisions that prioritise non-pharmacologic or DORA-based approaches. American Academy of Sleep Medicine 2024 guidance on restless-legs syndrome substitutes calcium-channel ligands for dopamine agonists to cut impulse-control disorders and augmentation risks. Real-world data confirm daridorexant’s lower serious adverse-event frequency; regulators across North America, Europe and APAC cite these findings when green-lighting wider indications. In parallel, auricular vagus-nerve stimulation has produced clinically meaningful sleep-quality gains without pharmacology, offering a drug-free refuge for risk-averse patients and reinforcing diversification within the sleep disorder treatment market.

High Cost of Branded Drugs and Advanced Devices Limiting Access in Low- and Middle-Income Regions

Pricing remains a formidable barrier beyond high-income markets. DORAs maintain premium positioning and have limited generic competition, making them aspirational therapies in South Asia and Sub-Saharan Africa despite strong clinical performance. Cloud-connected CPAP systems from ResMed demand capital outlays plus subscription fees that exceed average monthly income in many LMICs, curbing volume penetration although technical superiority is recognised. Insurance gaps aggravate disparity; Medicare debates on covering tirzepatide for OSA highlight how reimbursement policy drives real-world uptake, yet analogous coverage does not exist in most emerging economies. Online pharmacies soften price friction by boosting generic visibility; the global e-pharmacy sector touched USD 98.8 billion in 2022, though controlled-substance rules complicate cross-border fulfilment. Public systems can offset cost hurdles, illustrated by the UK National Health Service offering Sleepio without charge, a precedent that could be replicated in other tax-funded health models if robust cost-effectiveness evidence becomes available.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: DORAs Challenge Traditional Hypnotic Dominance

Non-benzodiazepines held 32.06% of the sleep disorder treatment market in 2025 as clinicians balanced familiarity with improved safety over benzodiazepines. Despite that anchor, DORAs are growing at 9.52% CAGR and are forecast to erode historical share as guidelines elevate orexin-based therapy to first-line status for chronic insomnia. Real-world pharmacovigilance confirms fewer residual cognitive effects and lower dependency signals, a combination that encourages payers to include DORAs on preferred tiers, thereby reinforcing volume growth within the sleep disorder treatment market.

Second-line classes remain relevant. Benzodiazepines are preserved for acute, severe insomnia when rapid onset is critical, though physicians now cap prescription lengths to mitigate dependence. Off-label antidepressants satisfy complex insomnia with comorbid mood disturbance, while melatonin receptor agonists dominate paediatric niches where neurodevelopmental safety outweighs speed. Pipeline momentum stays concentrated in orexin biology: Takeda’s oveporexton and Alkermes’ alixorexton promise once-daily oral dosing that could simplify current multi-dose oxybate regimens. These forces together keep the sleep disorder treatment market size for pharmacologic segments on a durable expansion path through 2031.

By Disorder Type: Narcolepsy Treatments Drive Innovation Pipeline

Insomnia disorders represented 38.86% of the sleep disorder treatment market size in 2025 owing to ubiquitous lifestyle, psychiatric and circadian contributors. Penetration of digital interventions such as SleepioRx and increasing employer wellness programmes signal that insomnia will remain the anchor indication; however, growth moderates as non-drug approaches divert some volume from legacy hypnotics. The December 2024 tirzepatide approval reshaped OSA management, creating the first drug-based alternative to CPAP and unlocking cardiometabolic-oriented care pathways that accelerate integrated management of obesity and sleep breathing disorders.

Narcolepsy accounts for a smaller base but rises fastest at 9.78% CAGR. Advancements in orexin-2 agonism address the fundamental neurochemistry deficit rather than symptom suppression, enticing venture and strategic capital even amid broader biotech volatility. FDA’s October 2024 nod for paediatric sodium oxybate broadened the treated population, while Avadel’s once-nightly LUMRYZ, granted seven years of orphan exclusivity, signals regulatory encouragement of differentiated formulations. These factors collectively ensure narcolepsy’s outsized contribution to incremental revenue inside the sleep disorder treatment market.

By Distribution Channel: Digital Transformation Accelerates Online Growth

Retail pharmacies maintained 41.98% share in 2025, leveraging in-person counselling, immediate fulfilment and broad insurer networks. High foot-traffic locations ensure consistent prescription volume, especially for chronic therapy refills. Hospital and sleep-clinic pharmacies anchor complex cases requiring titration of high-risk agents or synchronous device setups, yet they face capacity limits that incentivise remote models.

Online pharmacies are scaling at a 10.18% CAGR, benefitting from privacy, home delivery and transparent pricing that appeal to working-age adults managing chronic insomnia or OSA. Telehealth-based verification bridges regulatory compliance, and insurers increasingly reimburse virtual visits, shrinking friction further. Sunrise’s December 2024 acquisition of Dreem Health illustrates vertical integration of diagnostic wearables and digital care platforms, enabling entire diagnosis-to-dispense journeys to stay in-app and boosting lifetime engagement metrics. As a result, channel shifts will redistribute margins but expand overall access, fortifying the sleep disorder treatment market over the forecast horizon.

Geography Analysis

North America commanded 42.35% of the sleep disorder treatment market in 2025, supported by sophisticated payer systems that fast-track breakthrough therapies and by high public awareness of sleep’s impact on cardiometabolic health. FDA approvals for tirzepatide and multiple DORAs exemplify the regulator’s openness to novel mechanisms. Employer-driven wellness benefits, including subsidised Sleepio licences and CPAP subscription models, are normalising proactive sleep management. ResMed’s Q3 FY2025 revenue climbed 8% to USD 1.3 billion, reflecting robust demand for cloud-connected devices that integrate with electronic health-record workflows, thereby reinforcing adherence and reducing downstream hospitalisations.

Asia-Pacific is the fastest rising territory at 8.22% CAGR through 2031. China alone hosts 172.5 million insomnia sufferers, catalysing product localisation and broad-based formulary negotiations following DAYVIGO’s approval in May 2025. Japan’s September 2024 endorsement of QUVIVIQ broke a decade-long drought in novel insomnia therapies, sparking renewed clinician education campaigns and boosting prescription volume. South Korea’s Phase 3 daridorexant trial underscores regional regulatory momentum, while universities accelerate fundamental research, such as light-sensitive somnogen molecules under development at University of Tsukuba. Rising middle-class income and government initiatives to modernise sleep labs underpin sustained premium adoption, making Asia-Pacific the engine for volume and revenue expansion of the sleep disorder treatment market.

Europe maintains steady growth on the back of universal coverage and coordinated regulatory processes through the European Medicines Agency. Idorsia’s first-mover role with QUVIVIQ exploited EU-wide mutual recognition to build share before Merck’s Belsomra and Eisai’s Dayvigo entered, and public procurement emphasises price-volume agreements that favour drugs with proven safety and health-economic benefits. The UK National Health Service’s system-wide rollout of Sleepio free of charge exemplifies how digital therapeutics can penetrate large public systems and drive cost offsets, potentially unlocking similar models continent-wide. Multidisciplinary clinics such as Switzerland’s Sleep House Bern pilot fast triage pathways that could set new standards for European sleep-care delivery. Collectively, these trends keep Europe’s contribution to the sleep disorder treatment market resilient despite mature baseline adoption.

Regulatory Landscape

Regulation in sleep disorders treatment spans drug approvals, medical-device pathways, and oversight of clinically validated digital therapeutics. In the United States, the FDA has expanded labeled treatment options for obstructive sleep apnea (OSA) beyond devices, highlighted by the December 2024 approval of Zepbound (tirzepatide) as a pharmacologic therapy for moderate-to-severe OSA in adults with obesity. At the same time, the FDA continues to use the PMA pathway for implantable therapies in CPAP-intolerant populations, including the March 2026 premarket approval of LivaNova’s aura 6000 System (hypoglossal nerve stimulation) for moderate-to-severe OSA.

In Europe, the European Medicines Agency (EMA) and the European Commission maintain strict evidentiary standards for label expansions and pediatric indications, illustrated by the EMA-confirmed refusal (March 2026) to extend Hetlioz (tasimelteon) to certain pediatric sleep disturbances. EU regulation also supports cross-country commercialization once authorization is in place, reflected by Quviviq (daridorexant) maintaining an active EU marketing authorization per the EPAR updates. Policy workstreams to modernize EU medicinal-product procedures further point to continued emphasis on harmonized requirements for authorization, safety monitoring, and lifecycle changes across member states.

Market Opportunities and Future Outlook

A primary whitespace is the expansion of non-PAP pathways for OSA, where multiple modalities are progressing through late-stage regulation and clinical validation. The FDA’s March 2026 PMA approval of LivaNova’s aura 6000 hypoglossal nerve stimulation system broadens implantable options for adults with moderate-to-severe OSA who fail or are ineligible for PAP, reinforcing a growing segment between CPAP and more invasive surgical approaches. In oral OSA therapeutics, Apnimed’s July 2026 FDA acceptance of the AD109 NDA, with a PDUFA date of February 28, 2027, creates a near-term regulatory milestone that can support payer and provider engagement with pharmacologic alternatives for patients who do not persist with nightly device use.

Narcolepsy remains a concentrated innovation corridor where orexin biology is moving toward regulatory decision points, creating room for differentiated, mechanism-led entrants and for lifecycle management by incumbents. Takeda’s oveporexton (TAK-861) received FDA Priority Review acceptance (February 2026) for narcolepsy type 1, and Axsome’s AXS-12 NDA for cataplexy in narcolepsy was accepted for filing in July 2026. On the care-delivery side, combination therapy models are emerging for complex OSA phenotypes, supported by registered clinical research such as a June 2026 Brigham and Women’s Hospital trial evaluating pharmacological stimulation alongside hypoglossal nerve stimulation. This points to device-drug interoperability, shared data infrastructure, and new clinical pathways anchored in sleep-clinic and home-diagnostics ecosystems.